Maxim Group reaffirmed their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report published on Wednesday. The firm currently has a $35.00 price objective on the biopharmaceutical company’s stock.

“Abeona announced positive early data for ABO-101 in the first patient treated in the P1/2 trial for Sanfilippo Syndrome Type IIIB. As a reminder, this is the second gene therapy candidate targeting Sanfilippo Syndrome behind ABO-102, which has demonstrated positive data in 8 patients so far with Type IIIA disease. The difference between ABO-101 and ABO-102 is the replaced gene, same targeted pathway.”,” Maxim Group’s analyst wrote.

A number of other research analysts have also commented on the company. HC Wainwright set a $30.00 price objective on Abeona Therapeutics and gave the company a buy rating in a research report on Thursday, January 4th. Zacks Investment Research lowered Abeona Therapeutics from a buy rating to a hold rating in a research report on Thursday, November 23rd. SunTrust Banks started coverage on Abeona Therapeutics in a research report on Wednesday, November 8th. They issued a buy rating and a $26.00 price objective on the stock. Citigroup started coverage on Abeona Therapeutics in a research report on Tuesday, October 10th. They issued a buy rating and a $32.00 price objective on the stock. Finally, Cantor Fitzgerald increased their price objective on Abeona Therapeutics from $21.00 to $34.00 and gave the company an overweight rating in a research report on Wednesday, October 11th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $27.11.

Shares of Abeona Therapeutics (ABEO) opened at $18.20 on Wednesday. Abeona Therapeutics has a 12-month low of $4.55 and a 12-month high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.05. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.22 million. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. equities research analysts predict that Abeona Therapeutics will post -0.6 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Swiss National Bank bought a new position in shares of Abeona Therapeutics in the 4th quarter worth $794,000. California Public Employees Retirement System bought a new position in shares of Abeona Therapeutics in the 4th quarter worth $557,000. Teacher Retirement System of Texas bought a new position in shares of Abeona Therapeutics in the 4th quarter worth $163,000. SG Americas Securities LLC bought a new position in shares of Abeona Therapeutics in the 4th quarter worth $218,000. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Abeona Therapeutics by 37.1% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 56,352 shares of the biopharmaceutical company’s stock worth $894,000 after purchasing an additional 15,252 shares during the last quarter. Institutional investors and hedge funds own 41.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2018/02/08/abeona-therapeutics-abeo-rating-reiterated-by-maxim-group.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.